Navigation Links
GenomeDx Expands Collaboration with Mayo Clinic
Date:4/29/2013

SAN DIEGO, April 29, 2013 /PRNewswire/ -- GenomeDx Biosciences announced today that it has expanded an existing research agreement with the Mayo Clinic. The expanded agreement includes exclusive license to certain Mayo developed intellectual property along with exclusivity covering co-developed intellectual property.   The agreement also includes continued access to the clinical data concerning Mayo Clinic's cohort of prostate cancer samples to allow for longer-term follow up and evaluation of biomarkers. The initial collaboration entered in 2009 led to the development of Decipher™, a transformative genomic test that forecasts risk of metastasis in men with prostate cancer. In addition, GenomeDx announced that five studies evaluating the ability of Decipher to predict metastatic prostate cancer will be featured at the 2013 American Urological Association (AUA) Annual Meeting.

"Access to the Mayo Clinic's comprehensive cohort of samples from patients classified as high risk for metastatic disease and the involvement of Mayo Clinic researchers has been essential to the development of Decipher," said Doug Dolginow , M.D., Chief Executive Officer of GenomeDx. "With Mayo Clinic's large collection of patient samples that had developed metastatic disease, we could reliably identify and validate gene sequences associated with lethal prostate cancer and to create the Decipher test."

Abstracts Related to Decipher at AUA 2013

Podium presentation (May 8, 2013, 8:00-10:00 a.m. Pacific Time)

  • Validation of a genomic classifier that predicts metastatic disease progression in men with high risk pathological features post-prostatectomy, presented by R. Jeffrey Karnes , M.D., associate professor and Vice-Chair in Urology at Mayo Clinic
  • Location: San Diego Convention Center, Room 1

Poster presentations (May 8, 2013, 10:30 a.m.-12:30 p.m. Pacific Time)

  • Comparison of clinical and genomic models for prediction of rapid metastatic disease after radical prostatectomy, Abstract 2229; presented by Ashley Ross , M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
  • Performance of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy, Abstract 2240; presented by Ashley Ross , M.D., Ph.D., assistant professor in the departments of urology, oncology and pathology and Johns Hopkins School of Medicine
  • Combined value of genomic biomarkers and CAPRA-S in predicting prostate cancer death in a high-risk surgical cohort, Abstract 2243; presented by Matthew Cooperberg , M.D., assistant professor of urology; epidemiology & biostatistics, University of California, San Francisco
  • Evaluation of a genomic classifier for improved risk stratification in prostate cancer patients with specific adverse pathologies after surgery, Abstract 2230; presented by Doug Dolginow , M.D., CEO GenomeDx Biosciences
  • All posters located in San Diego Convention Center, Room 11

Abstracts for all Decipher studies presented at AUA can be found by searching for the keyword "Decipher" at http://www.aua2013.org/abstracts/index2.cfm.

About GenomeDx Biosciences
GenomeDx Biosciences develops and commercializes genomic tests for prostate and other urologic cancers that have a real impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs. The company's first test, Decipher™, is a transformative prognostic test that provides a direct measure of the true biological risk of metastatic prostate cancer independent of PSA and other risk factors. GenomeDx is based in San Diego, California and Vancouver, British Columbia. More information is available at www.genomedx.com.

Mayo Clinic has a financial interest in technology licensed to GenomeDx.


'/>"/>
SOURCE GenomeDx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millstone Medical Outsourcing Expands Medical Device Distribution Services
2. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
3. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
4. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
5. Western Maryland Health System Expands Use of Versus RTLS to Enhance Staff Safety
6. Compass Diversified Holdings Expands Term Loan Facility by $30 Million and Lowers Interest Rate by 1.25%
7. Phonak Expands Its Quest Platform with New Product Lines
8. Everyday Health Expands Solutions For Pharmaceutical Industry Marketers
9. BioElectronics Expands European Distribution to Malta
10. SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013
11. Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):